Global Veterinary Antibiotics Market 2026-2031 - Rising Livestock Disease Prevalence Drives Market Growth
Opportunities are rising in aquaculture, pet care, online pharmacies and long-acting injectables, while AMR rules shift demand toward narrow-spectrum, animal-only therapies.
Dublin, Aug. 21, 2026 (GLOBE NEWSWIRE) -- The "Veterinary Antibiotics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
Veterinary Antibiotics Market to Reach USD 6.36 Billion by 2031 as Animal Health Spending Increases
The global veterinary antibiotics market was valued at USD 5.40 billion in 2025 and is projected to increase from USD 5.55 billion in 2026 to USD 6.36 billion by 2031. The market is expected to register a compound annual growth rate of 2.75% during the forecast period, supported by rising demand for animal-source protein, growing companion-animal ownership and continued investment in livestock health.
Rising Demand for Animal-Source Protein Supports Market Growth
Global meat production rebounded in 2025, with poultry output rising 4.2% and pork production increasing 3.8% as restaurant activity and international trade recovered. Producers across Asia-Pacific and Latin America expanded intensive livestock operations to meet demand from China, the Middle East and other major importing markets.
This expansion continues to support demand for veterinary antibiotics in poultry, swine and cattle production. However, regional prescribing patterns are diverging. Developed markets increasingly favor narrow-spectrum, prescription-only therapies, while less-regulated markets continue to rely more heavily on over-the-counter broad-spectrum products. At the same time, global retailers and food exporters are introducing stricter antimicrobial stewardship requirements, encouraging the adoption of animal-specific antibiotic classes and more targeted treatment protocols.
Companion-Animal Ownership Strengthens Premium Demand
The rebound in pet ownership and veterinary expenditure is creating additional opportunities for the veterinary antibiotics market. In the United States, 67% of households owned a pet in 2025, representing an increase of four percentage points from 2023. Average veterinary spending per pet also rose 6.1% annually between 2024 and 2025.
Comparable trends are emerging across Europe and urban markets in Asia-Pacific. Greater use of diagnostic testing is supporting more precise prescribing, including aminoglycosides and first-generation cephalosporins for selected infections. Online veterinary pharmacies and tele-veterinary platforms are also gaining traction for prescription refills, although licensing requirements and telemedicine regulations continue to limit cross-border expansion.
Additional factors shaping the veterinary antibiotics market include:
- The regulatory transition toward animal-only antibiotic classes
- Expansion of injectable, heat-stable and long-acting formulations for ruminants
- Stricter antimicrobial resistance regulations affecting group treatments
- Increasing adoption of probiotics, phage-based products and other growth-promoter alternatives
Poultry Leads Revenue While Aquaculture Records Faster Growth
Poultry represented 32.55% of global veterinary antibiotics revenue in 2025, making it the leading animal segment. Preventive antibiotic use is increasingly restricted in Europe and North America, while substitution with ionophores and other alternatives is becoming more established.
Aquaculture generated USD 0.62 billion in 2025 and is forecast to expand at a 6.85% CAGR through 2031. Growth is particularly strong among shrimp and tilapia farms in Southeast Asia, where disease incidence remains high and access to approved fish-specific treatments is limited. These conditions can lead to off-label use of livestock medicines, creating both commercial opportunities and regulatory concerns.
Swine antibiotic demand remains relatively stable as precision-dose pleuromutilins replace bulk tetracyclines in some production systems. Cattle demand is divided between long-acting injectable treatments used in beef feedlots and intramammary products used in dairy operations. Companion-animal antibiotic sales continue to benefit from higher pet ownership and veterinary spending, while sheep and goats remain a smaller market concentrated primarily in the Mediterranean and Middle East.
Tetracyclines Retain the Largest Drug-Class Share
Tetracyclines accounted for 28.53% of veterinary antibiotics market revenue in 2025. Despite their leading position, tighter wastewater discharge requirements and medicated-feed directives are reducing routine group use in several markets.
Aminoglycosides generated USD 0.68 billion in revenue and are projected to grow at a 6.75% CAGR through 2031. Demand is being supported by veterinary use of gentamicin and amikacin for respiratory and urinary infections, particularly among companion animals.
Penicillins and first-generation cephalosporins remain important in dairy mastitis treatment, while third-generation cephalosporins face stricter reserve classifications. Macrolides, including long-acting tulathromycin formulations, continue to gain adoption in bovine respiratory disease management. Fluoroquinolone volumes are declining following aquaculture restrictions in China and tighter European regulations, while sulfonamides face pressure from combination therapies that provide greater efficacy at lower doses.
Regional Veterinary Antibiotics Market Outlook
North America accounted for 32.52% of global revenue in 2025. Growth is constrained by veterinary feed directives, restrictions on over-the-counter sales and shortages of rural veterinarians. Nevertheless, premium companion-animal spending and demand for long-acting cattle injectables continue to support market value.
Asia-Pacific is projected to expand at a 6.12% CAGR through 2031, making it a key growth region. Genotyping mandates in China and dairy-sector modernization in India are supporting demand for targeted therapies. Meanwhile, less-regulated aquaculture markets in Southeast Asia continue to generate broad-spectrum antibiotic sales, although residue risks may create challenges for exporters serving markets with stringent import standards.
Europe is managing increasingly rigorous antimicrobial resistance and wastewater regulations, which are raising compliance costs across the veterinary pharmaceutical sector. Latin America presents mixed conditions: export-oriented producers in Brazil are aligning with importing-country protocols, while domestic livestock operations continue to rely more heavily on over-the-counter products. In the Middle East and Africa, Gulf countries import premium veterinary formulations, whereas many sub-Saharan markets depend on generic products distributed through agricultural cooperatives with limited veterinary oversight.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Surging Global Demand for Animal-Source Protein Post-Pandemic
4.2.2 Rebound in Companion-Animal Ownership and Veterinary Expenditure
4.2.3 Regulatory Shift Toward Animal-Only Antibiotic Classes
4.2.4 Expansion of Injectable, Heat-Stable Long-Acting Formulations
4.2.5 Livestock Genotyping and on-Farm Diagnostics for Precision Dosing
4.2.6 Unmonitored Antibiotic Use in ASEAN Aquaculture
4.3 Market Restraints
4.3.1 Tightening AMR Regulations Reducing Group Treatments
4.3.2 Rapid Penetration of Probiotic / Phage Growth-Promoter Alternatives
4.3.3 Chronic Shortage of Rural Veterinarians and Skilled Farm Labor
4.3.4 EU Wastewater and ERA Rules Lifting Compliance Costs for Generics
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Animal Type
5.1.1 Poultry
5.1.2 Swine
5.1.3 Cattle
5.1.4 Sheep & Goats
5.1.5 Companion Animals
5.1.6 Aquaculture
5.1.7 Other Livestock
5.2 By Drug Class
5.2.1 Tetracyclines
5.2.2 Penicillins
5.2.3 Sulfonamides
5.2.4 Macrolides
5.2.5 Aminoglycosides
5.2.6 Cephalosporins
5.2.7 Fluoroquinolones
5.2.8 Others
5.3 By Delivery Form
5.3.1 Premixes
5.3.2 Oral Powders
5.3.3 Oral Solutions
5.3.4 Injections
5.3.5 Intramammary & Intra-uterine
5.3.6 Feed-Additive Blends
5.4 By Spectrum of Activity
5.4.1 Broad-Spectrum
5.4.2 Narrow-Spectrum
5.5 By End User
5.5.1 Food-Producing Animal Producers
5.5.2 Companion-Animal Owners
5.6 By Distribution Channel
5.6.1 Veterinary Hospitals & Clinics
5.6.2 Retail Pharmacies
5.6.3 Online Channels
5.7 Geography
5.7.1 North America
5.7.1.1 United States
5.7.1.2 Canada
5.7.1.3 Mexico
5.7.2 Europe
5.7.2.1 Germany
5.7.2.2 United Kingdom
5.7.2.3 France
5.7.2.4 Italy
5.7.2.5 Spain
5.7.2.6 Rest of Europe
5.7.3 Asia-Pacific
5.7.3.1 China
5.7.3.2 India
5.7.3.3 Japan
5.7.3.4 Australia
5.7.3.5 South Korea
5.7.3.6 Rest of Asia-Pacific
5.7.4 Middle East and Africa
5.7.4.1 GCC
5.7.4.2 South Africa
5.7.4.3 Rest of Middle East and Africa
5.7.5 South America
5.7.5.1 Brazil
5.7.5.2 Argentina
5.7.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 AdvaCare Pharma LLP
6.3.2 Ashish Life Science Private Limited
6.3.3 Bimeda Holdings Limited
6.3.4 Boehringer Ingelheim Animal Health International GmbH
6.3.5 Ceva Sante Animale S.A.
6.3.6 Chanelle Pharma Private Limited
6.3.7 Dechra Pharmaceuticals Limited
6.3.8 Elanco Animal Health Incorporated
6.3.9 HIPRA, S.A
6.3.10 Huvepharma
6.3.11 KRKA d.d.
6.3.12 Kyoritsu Seiyaku
6.3.13 Merck Animal Health (MSD)
6.3.14 Norbrook
6.3.15 Ourofino Saude Animal
6.3.16 Phibro Animal Health
6.3.17 Vetoquinol
6.3.18 Virbac
6.3.19 Zoetis
6.3.20 Zydus Animal Health
7 Market Opportunities & Future Outlook
7.1 White-Space & Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/odegrh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
